CCA EDUCATE
CHOLANGIOCARCINOMA AUSTRALASIA
RESEARCH | MUTATIONS | TREATMENT | SURGERY
A seismic shift has occurred in cancer therapy unleashing the adaptive immune response.
Extract of Beyond the Blockade
Looking through the blockade
UW Video
Published on May 18, 2018
A seismic shift has occurred recently in cancer therapy. Multiple agents that unleash the adaptive immune response against tumors have been FDA-approved and found to induce remarkable results in a subset of patients with advanced cancers. The mechanistic basis for these checkpoint inhibitor therapies and new agents in development that could augment their activity will be discussed. After viewing this lecture, participants should be able to: 1. List the 4 main steps involved in inducing a durable and effective adaptive immune response. 2. Explain how checkpoint blockade enhances immune responses to tumors. 3. List at least 3 effects that IL-15 has or doesn’t have on lymphocytes that make it an attractive immunotherapy agent. Chihiro Morishima, MD Director, Research Testing Services Co-Director, Clinical Immunology Laboratory Associate Professor, Department of Laboratory Medicine University of Washington
05/09/18
http://depts.washington.edu/labweb/Ed…
http://uwtv.org
WHAT ARE TUMOUR MARKERS
A tumor marker is anything present in or produced by cancer cells or other cells of the body in response to cancer or certain benign (noncancerous) conditions that provides information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment.
Tumor markers have traditionally been proteins or other substances that are made by both normal and cancer cells but at higher amounts by cancer cells. These can be found in the blood, urine, stool, tumors, or other tissues or bodily fluids of some patients with cancer. Increasingly, however, genomic markers such as tumor gene mutations, patterns of tumor gene expression, and nongenetic changes in tumor DNA, are being used as tumor markers.
Many different tumor markers have been characterized and are in clinical use. Some are associated with only one type of cancer, whereas others are associated with multiple different cancer types. No “universal” tumor marker has been found that can reveal the presence of any type of cancer.
